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Abstract
Background
Advance care planning (ACP) supports individuals to define, discuss, and record goals and
preferences for future medical treatment and care. Despite being internationally recom-
mended, randomised clinical trials of ACP in patients with advanced cancer are scarce.
Methods and findings
To test the implementation of ACP in patients with advanced cancer, we conducted a clus-
ter-randomised trial in 23 hospitals across Belgium, Denmark, Italy, Netherlands, Slovenia,
and United Kingdom in 2015–2018. Patients with advanced lung (stage III/IV) or colorectal
(stage IV) cancer, WHO performance status 0–3, and at least 3 months life expectancy
were eligible. The ACTION Respecting Choices ACP intervention as offered to patients in
the intervention arm included scripted ACP conversations between patients, family mem-
bers, and certified facilitators; standardised leaflets; and standardised advance directives.
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Control patients received care as usual. Main outcome measures were quality of life (opera-
tionalised as European Organisation for Research and Treatment of Cancer [EORTC] emo-
tional functioning) and symptoms. Secondary outcomes were coping, patient satisfaction,
shared decision-making, patient involvement in decision-making, inclusion of advance
directives (ADs) in hospital files, and use of hospital care. In all, 1,117 patients were included
(442 intervention; 675 control), and 809 (72%) completed the 12-week questionnaire.
Patients’ age ranged from 18 to 91 years, with a mean of 66; 39% were female. The mean
number of ACP conversations per patient was 1.3. Fidelity was 86%. Sixteen percent of
patients found ACP conversations distressing. Mean change in patients’ quality of life did
not differ between intervention and control groups (T-score −1.8 versus −0.8, p = 0.59), nor
did changes in symptoms, coping, patient satisfaction, and shared decision-making. Spe-
cialist palliative care (37% versus 27%, p = 0.002) and AD inclusion in hospital files (10%
versus 3%, p < 0.001) were more likely in the intervention group. A key limitation of the
study is that recruitment rates were lower in intervention than in control hospitals.
Conclusions
Our results show that quality of life effects were not different between patients who had ACP
conversations and those who received usual care. The increased use of specialist palliative
care and AD inclusion in hospital files of intervention patients is meaningful and requires fur-
ther study. Our findings suggest that alternative approaches to support patient-centred end-
of-life care in this population are needed.
Trial registration
ISRCTN registry ISRCTN63110516.
Author summary
Whywas this study done?
• Advance care planning (ACP) has been widely advocated as an approach to support
patients, relatives, and healthcare professionals in reflecting on and discussing patients’
preferences and to adapt care and treatment accordingly.
• There is little evidence of its effectiveness in relation to patients with advanced cancer in
Europe.
What did the researchers do and find?
• We conducted a study in 23 hospitals in 6 European countries, including 1,117 patients
with advanced lung or colorectal cancer.
• Depending on the hospital where they were treated, they were offered ACP conversa-
tions with a certified facilitator or they were offered care as usual.
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• Sixty-seven percent of patients considered the ACP conversations helpful, and most
patients who took part in the ACP conversations appointed a relative who could repre-
sent their interests if they would not be able to do so themselves.
• Thirty-seven percent of patients in the intervention group completed a form to record
their preferences for future care.
• We found that ACP conversations did not have an impact on patients’ quality of life,
coping, or involvement in decision-making processes; patients who had had ACP con-
versations more often received specialist palliative care.
What do these findings mean?
• The findings of the ACTION study did not provide evidence to support the use of a
structured ACP intervention to improve the quality of life of patients affected by
advanced lung or colorectal cancer.
• There is some evidence that patients taking part in ACP conversations were more likely
to receive palliative care, and more likely to have their documented preferences
recorded in their medical records.
• Further research is required to establish how patients can best be supported to formulate
and, if they wish, to document their preferences for future care.
Introduction
End-of-life discussions between patients, relatives, and healthcare professionals are associated
with less burdensome interventions near death, earlier hospice referrals [1], improved emo-
tional functioning [2,3], and better symptom resolution [3]. Still, timely and adequately pro-
viding patients and their families with an opportunity to prepare for the changes wrought by
serious progressive illness and to explore patients’ preferences is a challenge [4,5]. Advance
care planning (ACP) enables individuals to define goals and preferences for future medical
treatment and care, to discuss these goals and preferences with family and healthcare provid-
ers, and to record and review these preferences if appropriate [6]. ACP interventions have the
potential to prepare patients for decision-making when they are unable to make their own
decisions. ACP interventions typically include 1 or more focused, personal conversations
between patients and healthcare professionals about patients’ personal values, life goals, and
preferences regarding future medical treatment and care. Such conversations have been
reported to reduce hospital admissions at the end of life, to increase compliance of provided
care with patients’ wishes, and to increase satisfaction with care among older people and nurs-
ing home residents [7].
While ACP is a promising approach to improve the quality of life of patients with advanced
cancer [7,8], evidence on its effectiveness for this patient group is limited [9]. We updated a
2019 systematic review of randomised controlled trials (RCTs) about ACP for patients with
advanced cancer [10] and identified 6 RCTs of complex ACP interventions for advanced can-
cer patients: 1 conducted in the UK (n = 77) [11], 2 in Australia (n = 120–208) [12,13], and 3
in the US (n = 155–278) [14–16]. In these studies, ACP was found to increase the proportion
of patients engaging in conversations about future medical treatment and care, but not to
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affect satisfaction with healthcare. No effects on place of death and treatment received at the
end of life were found, while conflicting results were reported about the completion of advance
directives (ADs) and patients’ quality of life. All RCTs were at high risk of performance bias,
attrition bias, or other kinds of bias. We therefore performed a large-scale RCT in 6 European
countries to evaluate the effects of a complex ACP intervention on the quality of life, operatio-
nalised as emotional functioning, and symptoms of patients with advanced lung or colorectal
cancer. Secondary outcomes were coping, patient satisfaction, shared decision-making, patient
involvement in decision-making, AD inclusion in hospital files, and use of hospital care.
Methods
Study design
ACTION is a multicentre cluster-randomised controlled trial carried out in 23 hospitals in 6
European countries (Belgium, Denmark, Italy, the Netherlands, Slovenia, and the United
Kingdom). We opted for cluster randomisation to prevent contamination. Using a computer-
based generator tool, per country and per pair of comparable hospitals (academic or non-aca-
demic), hospitals were randomised by the study coordinator to the intervention arm, provid-
ing usual care and ACP, or the control arm, providing usual care. Per hospital usually 2
departments participated, e.g., a pulmonology and an oncology department. All patients with
advanced lung (stage III or IV) or colorectal cancer (stage IV), WHO performance status 0–3,
an estimated life expectancy of at least 3 months, and competence to give consent were eligible
(see S1 Text). When a care team considered patients eligible, they were asked to consider par-
ticipation in ACTION. Patients who wanted to consider participation were contacted by the
researcher team and provided with more information about the study. Patients in the interven-
tion hospitals received information about the intervention. Those in control hospitals were
informed that ACTION focused on preparing patients for decision-making about care,
and that they would receive usual care. Patients were given unrestricted time to consider par-
ticipation and were informed that they were free to withdraw from participating in the study
without any effect on their care. Patients who provided written informed consent were
included and followed until 12 months after inclusion. The trial procedures have been
described in detail in a protocol paper [17]. The trial was registered in the ISRCTN registry
(ISRCTN63110516) as of 10 March 2014. We report the study according to CONSORT report-
ing guidelines.
The intervention
Respecting Choices (RC) is a comprehensive, structured ACP programme that was developed
in La Crosse, Wisconsin, in the US (https://respectingchoices.org/). RC was successfully
trialled among older people in Australia [18]. We developed and evaluated the ACTION RC
ACP intervention. This was an adapted and integrated version of 2 of the 3 stages of the RC
facilitated ACP conversations (First Steps and Advanced Steps). The ACTION RC ACP inter-
vention includes 3 components (see S2 Text): (1) facilitated structured ACP conversations, (2)
the My Preferences form, and (3) information leaflets.
Facilitated structured ACP conversations. Healthcare professionals who were certified
to deliver the ACTION RC ACP intervention used scripted conversation guides to support
patients and their relatives in exploring their understanding of the illness; reflecting on their
goals, values, and beliefs; and discussing their preferences for future treatment and care.
Depending on the choice of the patient, the intervention involved 1 or 2 conversations, with or
without a personal representative being present. Conversations took place in the hospital or at
patients’ homes.
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My Preferences form. The My Preferences form is a study-specific form where patients
can document their preferences (see S3 Text). Depending on local regulations, the My Prefer-
ences form may be considered as a formal AD or an informal expression of wishes. It was
developed in an iterative process with input from stakeholders, including patient representa-
tives, clinicians, and researchers from all participating countries. It consists of open sections
regarding ‘living well’, ‘worries and fears’, ‘beliefs’, and ‘hopes’, and structured sections to indi-
cate preferences regarding cardiopulmonary resuscitation (CPR), goals of future care, and
final place of care. Patients were offered the option of completing a My Preferences form,
either during or after the ACP conversation. They were advised that they could provide copies
to their family and healthcare professionals and could adapt their My Preferences form if
needed.
Information leaflets. Information leaflets regarding ACP and the role of the personal rep-
resentative were provided to all patients who participated in the intervention. Where relevant,
patients were also provided with information leaflets about CPR, artificial ventilation, and arti-
ficial feeding.
Cross-cultural adaption of intervention and training materials was required to make them
appropriate for the countries in this study whilst maintaining the essentials of the content,
structure, and integrity of the original intervention. Materials were tested in a feasibility study
with 53 patients, 18 relatives, and 29 healthcare professionals and subsequently finalised. Aim-
ing for maximum uniformity in the delivery of the intervention across the 6 countries, all
ACTION RC instructors followed the RC First and Advanced Steps training programme
together. In each country, an ACTION RC instructor provided facilitators with a 2-day com-
petency-based training programme, in the local language. In total, 39 facilitators, predomi-
nantly nurses, were certified.
Per facilitator, fidelity checks were conducted twice, once halfway through the inclusion
period and once towards the end of the inclusion period. ACP conversations were audio-
recorded, and facilitators’ compliance with the conversation intervention was systematically
evaluated by local ACTION RC instructors, using a pilot-tested fidelity checklist that covered
the key elements of the conversation guides.
Outcome measures
At baseline and at 11–12 weeks (follow-up assessment 1) and 19–20 weeks (follow-up assess-
ment 2) after inclusion, patients completed a written questionnaire. Quality of life, assessed
with 10 items of the European Organisation for Research and Treatment of Cancer (EORTC)
emotional functioning item bank [19–21] and symptoms (EORTC QLQ-C15-PAL [22]) were
the primary outcomes. Secondary outcomes were coping (COPE, Brief COPE [23–25]), satis-
faction with care (items of the EORTC IN-PATSAT [26]), satisfaction with the intervention (9
study-constructed items), shared decision-making (Assessment of Patients’ Experience of
Cancer Care [APECC] decision-making self-efficacy scale [27]), and patient involvement in
medical decision-making (4 study-constructed items). The availability of completed ADs in
the hospital medical file and use of medical care were extracted from medical files in the hospi-
tal where patients were recruited. A medical file checklist was developed to allow structured
and uniform data collection at 1 year post-inclusion. Due to closure of the data collection,
medical files were not checked for patients included after 30 April 2017.
Statistical analysis
We aimed at an overall power of 0.9 (alpha 0.05) to detect a difference between the interven-
tion and control group at the first follow-up assessment of at least 0.5 standard deviation on
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the 4-item emotional functioning scale (EF4) of the EORTC-QLQ-C30, assuming an intraclass
correlation coefficient (ICC) of 0.1 [17]. We expected to include patients in at least 10 inter-
vention and 10 control hospitals (40 departments). We anticipated around 15% of included
patients would die before the first follow-up assessment and about 10% would drop out, result-
ing in an expected attrition rate of 25%. We therefore needed to include 68 participants per
hospital, resulting in 1,360 patients [17]. Originally, 22 hospitals were randomised. For logistic
reasons, no patients were included in 1 hospital. During the study, 2 additional hospitals were
randomised to increase the inclusion rate, resulting in a total number of 23 hospitals.
When during data collection the EORTC emotional function 10-item short form (EF10)
appeared to have better precision and relative validity than EF4 [28], we opted for EF10 as our
primary outcome measure; the new target number of patients while maintaining the same
power was 1,088.
Statistical analyses were by intention-to-treat. Patients lost to follow-up and other missing
information were taken into account by performing a multiple imputation (MI) procedure
[29]. The MI procedure was implemented using the Multivariate Imputation by Chained
Equations (MICE) algorithm withM = 37 imputations [30]. At the end of the MICE procedure
we analysed each of theM complete datasets applying standard statistical methods and we
combined the results according to Rubin’s rule [29] (see Box A, Table A, and Table B in S4
Text). We compared differences in change scores between the 2 arms and evaluated the associ-
ation between treatment and each outcome measure using a multilevel regression model with
random intercept adjusted for the baseline value of the measure, allowing us to take into
account the intraclass correlation occurring between patients attending the same hospital.
Assuming that the RC ACP intervention would not have influenced survival, we planned to
perform the analyses on the subset of patients who survived until the first and second follow-
up assessments. Moreover, we checked for determinants of emotional functioning apart from
the intervention and for an interaction effect of the intervention and country using a multilevel
regression model that took into account clustering at the hospital level. The model was
adjusted for the baseline level of the measure, country, and individual characteristics (i.e., sex,
having children, age, years of education, living with a spouse/partner, living place, religiosity,
WHO performance status, current treatment, and cancer stage and type) selected on the basis
of the Akaike information criterion for each imputed dataset [31]. Differences were considered
significant if p< 0.05 (see Table C in S4 Text).
Ethics
Ethical approval was obtained from research ethics committees in the coordinating centre at
Erasmus MC (NL50012.078.14, v02) and in all participating countries. An international data
and safety monitoring board monitored the trial and conducted 4 interim analyses during data
collection.
Results
Participation and feasibility
Between 21 May 2015 and 6 February 2018, 3,748 patients were considered eligible, 2,748
(73%) were asked to participate, and 1,135 provided consent to participate. Of these, 5 with-
drew their consent. The recruitment rate was 29% in the intervention group (445/1,523) versus
56% in the control group (685/1,225). Thirteen patients did not complete any questionnaires.
We included data of 1,117 patients in the analyses (442 in the intervention group and 675 in
the control group; see Fig 1). Patients’ mean age was 66 years. In both groups, the majority of
patients received systemic anti-cancer treatment at the time of study inclusion (Table 1).
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During the 1-year follow-up period, 194 patients in the intervention group (44%) and 263
(39%) in the control group died: 30 patients in the intervention group (7%) and 55 patients in
the control group (8%) died before follow-up assessment 1, whereas 57 (13%) and 109 (16%)
patients, respectively, died before follow-up assessment 2.
Intervention delivery
In the intervention group, 396 patients participated in ACP conversations (90%). Patients had
on average 1.3 ACP conversations, which had a mean length of 93 minutes. Fidelity analyses
showed that on average 86% of the key elements of the intervention were discussed.
Primary and secondary outcome measures
Since the assumption that the RC ACP intervention did not influence survival was satisfied
(p = 0.57 and p = 0.41 at follow-up assessments 1 and 2, respectively), we performed the analy-
ses on the subset of patients who survived until the first and second follow-up assessments
(92% and 85% of the sample, respectively). Of patients who survived, 22% and 26% were lost
to follow-up at the first and second follow-up assessments, respectively. We found no
Fig 1. Participant flowchart.
https://doi.org/10.1371/journal.pmed.1003422.g001
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statistically significant differences between the intervention and control group in change in
EORTC emotional functioning score (EF10) at the first (−1.8 versus −0.8, p = 0.59; Table 2) or
second (−2.3 versus −0.2, p = 0.10) follow-up assessment. Further analyses showed that there
was no interaction effect of intervention and country either (p = 0.41).
Table 1. Sociodemographic and clinical characteristics of ACTION participants.
Characteristic Intervention group (n = 442) Control group (n = 675)
Sociodemographic characteristics
Years of education, mean (SD) 13.1 (4.5) 12.9 (4.7)
Missing 56 94
Female sex, n (%) 173 (39) 268 (40)
Living with a spouse/partner, n (%) 303 (69) 497 (74)
Missing 10 17
Having children, n (%) 376 (85) 583 (86)
Missing 8 7
Religiosity, n (%)
Religious 207 (47) 341 (51)
Not religious 174 (39) 228 (34)
Prefers not to specify 51 (12) 93 (14)
Missing 10 13
Considering oneself member of minority group, n (%) 3 (1) 7 (1)
Missing 18 26
Country of residence, n (%)
Belgium 72 (16) 135 (20)
Denmark 68 (15) 68 (10)
Italy 31 (7) 139 (21)
Netherlands 84 (19) 168 (25)
Slovenia 72 (16) 25 (4)
United Kingdom 115 (26) 140 (21)
Clinical characteristic
Diagnosis, n (%)
Lung cancer, stage III or IV 271 (62) 339 (50)
Colorectal cancer, stage IV 171 (38) 336 (50)
Years since diagnosis, mean (SD) 1.2 (1.7) 1.7 (2.4)
Range 0.1–11.5 0.1–33.3
Missing 7 1
Years since diagnosis of current stage, mean (SD) 0.6 (0.9) 1.0 (1.4)
Range 0–6 0–11
Missing 2 3
Receiving systemic treatment1, n (%) 349 (79) 595 (89)
Missing 2 3
WHO performance status2, n (%)
3 In bed/ sitting for more than half of the day 10 (2) 8 (1)
2 Up for more than half of the day 74 (17) 55 (8)
1 No heavy psychical work 243 (55) 343 (51)
0 Fully active 109 (25) 261 (39)
Missing 6 8
1Includes chemotherapy, immunotherapy, and targeted therapy.
https://doi.org/10.1371/journal.pmed.1003422.t001
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Change scores did not differ between arms for the EORTC QLQ-C15-PAL scales, coping,
satisfaction with care, patient involvement in decision-making, or shared decision-making
(Table 2). In the intervention group, 147 of 396 (37%) patients who had ACP conversations
provided their facilitators with a copy of their completed My Preferences form. It is not known
how many others completed the My Preferences form or another document indicating their
preferences.
We analysed the medical files of 365 patients (83%) in the intervention group and of 583
control patients (86%). At 12 months post-inclusion, 37 medical files (10%) of patients in the
intervention group contained ADs versus 15 in the control group (3%; p< 0.001). Indications
that personal representatives were appointed were more often found in medical files of patients
in the intervention group (33 versus 7 times, p< 0.001). During the 12 months of follow-up,
61% of patients in the intervention group and 56% of patients in the control group were
Table 2. ICC and changes in outcome scores between follow-up assessment 1 and baseline and follow-up assessment 2 and baseline (with 95% confidence intervals),
with p-values frommultilevel regression model with random intercept and with hospital as random level adjusting for baseline levels of each endpoint.
Outcome Follow-up assessment 1 versus baseline Follow-up assessment 2 versus baseline
ICC Intervention group
(n = 412)
Control group
(n = 620)
p-
Value
ICC Intervention group
(n = 385)
Control group
(n = 566)
p-
Value
Emotional functioning (EORTC EF10)� 0.030 −1.8 (−4.2, 0.7) −0.8 (−1.5, −0.1) 0.59 0.001 −2.3 (−5.8, 1.2) −0.2 (−1.4, 0.9) 0.10
Quality of life and symptoms (EORTC QLQ-C15-PAL)^
Overall quality of life 0.053 −5.7 (−14.2, 2.9) −2.0 (−4.0, 0.1) 0.22 0.026 −5.4 (−13.8, 2.9) −1.4 (−3.6, 0.8) 0.23
Emotional functioning 0.030 −3.6 (−8.2, 1.1) −1.7 (−3.4, 0.1) 0.90 0.003 −5.0 (−12.5, 2.5) −3.3 (−7.5, 1.0) 0.95
Physical functioning 0.049 −6.5 (−16.3, 3.3) −5.6 (−14.0, 2.9) 0.56 0.022 −8.8 (−23.1, 5.4) −5.5 (−13.8, 2.8) 0.06
Pain 0.015 6.0 (−9.7, 21.6) 4.3 (−7.4, 16.0) 0.45 0.019 8.4 (−12.4, 29.1) 3.9 (−6.9, 14.7) 0.05
Dyspnoea 0.045 5.4 (−9.7, 20.5) 4.5 (−7.9, 16.8) 0.53 0.030 5.8 (−10.5, 22.1) 5.5 (−9.2, 20.2) 0.63
Insomnia 0.031 −0.9 (−4.5, 2.7) 1.0 (−4.5, 6.5) 0.29 0.034 2.6 (−7.5, 12.7) −0.3 (−4.2, 3.6) 0.42
Appetite loss 0.036 5.2 (−9.7, 20.2) 3.8 (−7.3, 14.9) 0.69 0.023 8.6 (−13.4, 30.6) 5.9 (−9.8, 21.5) 0.38
Constipation 0.024 1.2 (−5.8, 8.2) 2.2 (−5.6, 10.0) 0.69 0.023 1.0 (−5.8, 7.7) 3.5 (−7.0, 14.1) 0.75
Fatigue 0.026 5.3 (−9.1, 19.7) 2.8 (−6.0, 11.5) 0.36 0.025 7.0 (−11.1, 25.1) 3.5 (−6.8, 13.8) 0.15
Nausea/vomiting 0.010 2.7 (−6.0, 11.4) 2.0 (−4.8, 8.9) 0.88 0.010 3.2 (−6.6, 13.0) 3.4 (−6.1, 12.8) 0.99
Shared decision-making (APECC decision-
making self-efficacy scale)^
0.098 −3.3 (−7.3, 0.7) −1.8 (−3.6, 0) 0.77 0.095 −2.5 (−5.0, 0.1) −3.2 (−6.9, 0.6) 0.24
Patient involvement in medical decision-
making^
0.022 1.7 (−4.5, 7.8) −1.9 (−3.9, 0.2) 0.33 0.026 2.5 (−5.4, 10.3) −1.9 (−4.2, 0.4) 0.33
Coping (COPE)^
Denial 0.040 0.2 (−4.4, 4.8) 2.6 (−5.6, 10.7) 0.63 0.070 1.0 (−5.1, 7.0) 2.8 (−6.0, 11.5) 0.75
Acceptance 0.067 −3.7 (−8.2, 0.9) −3.0 (−6.6, 0.6) 0.58 0.040 −5.7 (−14.1, 2.7) −3.2 (−7.2, 0.8) 0.99
Problem focused 0.079 −4.8 (−11.0, 1.5) −3.7 (−8.6, 1.2) 0.76 0.073 −5.0 (−11.5, 1.6) −3.6 (−8.0, 0.8) 0.78
Satisfaction with care (EORTC IN-PATSAT)^
Information provision by doctors 0.055 −3.3 (−6.8, 0.2) −3.3 (−7.4, 0.9) 0.59 0.060 −2.6 (−5.1, −0.1) −5.4 (−13.7, 2.9) 0.57
Information provision by nurses 0.046 −3.3 (−7.1, 0.5) −3.9 (−9.0, 1.3) 0.56 0.047 −3.3 (−7.1, 0.6) −5.6 (−14.1, 3.0) 0.23
General rating of received care 0.067 −3.9 (−9.1, 1.3) −4.5 (−11.2, 2.1) 0.54 0.054 −5.0 (−12.5, 2.4) −6.3 (−16.4, 3.8) 0.45
The analyses are performed on imputed data (M = 37 imputations) on patients who survived to follow-up assessment 1 (N = 1,032; 85 deaths before follow-up
assessment 1) for analyses on follow-up assessment 1 and on patients who survived to follow-up assessment 2 (N = 951; 166 deaths before follow-up assessment 2) for
analyses on follow-up assessment 2.
�The score is transformed to a T-score metric with a general population mean of 50 (standard deviation 10).
^Possible score ranges from 0 to 100.
APECC, Assessment of Patients’ Experience of Cancer Care; EF10, emotional function 10-item short form; EORTC, European Organisation for Research and
Treatment of Cancer; ICC, intraclass correlation coefficient.
https://doi.org/10.1371/journal.pmed.1003422.t002
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hospitalised (p = 0.14). Their average number of inpatient hospital days was 15 and 14, respec-
tively (p = 0.5; Table 3). In the intervention group, relatively more patients had used specialist
palliative care services (n = 134 [37%] versus n = 160 [27%]; p = 0.002; Table 3).
Sixty-seven percent of patients considered the ACP conversations ‘quite or very helpful’,
and 16% considered them ‘quite or very stressful’ (Table 4). Three serious adverse events
(SAEs) related to the intervention were reported: 1 patient was distressed after reading the
study materials and 2 after an ACP conversation. These SAEs were resolved.
Discussion
We performed a large randomised controlled trial evaluating the effects of ACP. In 23 hospitals
across 6 countries, we included 1,117 patients with advanced lung or colorectal cancer.
Patients in the intervention group had ACP conversations with certified facilitators. We did
not find any difference in effect on patients’ quality of life, symptoms, coping, satisfaction with
care, or shared decision-making at 11–12 weeks post-inclusion, nor did we find an effect on
hospital admissions during 1 year of follow-up compared to the control group. Patients in the
intervention group used specialised palliative care more often. Hospital files of patients in the
intervention group contained ADs, and indications of appointed personal representatives as
part of the ADs, more often than those of patients in the control group.
In both the intervention and the control arm, scores for shared decision-making, informa-
tion as provided by doctors or nurses, and the rating of care as received declined from baseline.
This unexpected finding could potentially be explained by increased awareness through study
participation of the complexity of decision-making and information provision.
Strengths and limitations
An important feature of our trial is its pragmatic nature, focusing on actual practice in coun-
tries with different healthcare systems and end-of-life care cultures, and varying degrees of
familiarity with ACP, which increases the external validity and generalisability of our findings.
Table 3. The documentation of preferences in medical files and the use of hospital care.
Outcome Intervention group (n = 442) Control group (n = 675) p-Value
AD in medical file
Completed AD in medical file, n (%) 37 (10) 15 (3) <0.001�
Missing 77 92
Type of AD, n (%)
My Preferences form 31 Not applicable
Other AD 8 (2) 15 (3) 0.71�
Appointment of personal representative, n (%) 33 (28 MPF, 4 other, 1 both) (94) 7 (47) <0.001�
Missing 2 0
Hospital care
Any hospitalisation, n (%) 222 (61) 328 (56) 0.17�
Missing 77 92
If any hospitalisation, number of days, mean (SD, range) 15 (13, 0–63) 14 (13, 0–75) 0.53^
Use of specialist palliative care, n (%) 134 (37) 160 (27) 0.002�
Missing 78 92
�Chi-squared test on observed values.
^Unpaired t test.
AD, advance directive; MPF, My Preferences form.
https://doi.org/10.1371/journal.pmed.1003422.t003
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An additional strength is the high-quality research design in which we evaluated a uniform,
multi-component ACP intervention that included structured, facilitated conversations, a uni-
form cross-cultural training programme, and fidelity evaluations. In addition, we developed
the My Preferences form, aiming to enable participants to document their preferences in a for-
mat that was socially, culturally, legally, and ethically acceptable in all 6 participating countries.
In a content analysis of 123 My Preferences forms, it was found that 43.9% of patients opted
for comfort-focused care only; 75 preferred home as the final place of care, 20 preferred hos-
pice, and 10 preferred hospital [32]. We included 1,117 patients, which is above the target
number of 1,088 [28]. The ICC as observed for the primary outcome (EF10) turned out to be
smaller than was assumed at the design stage, thus enhancing the trial power [33].
The study also has limitations. First, fewer eligible patients in the intervention group were
asked to participate than in the control group (66% versus 84%), suggesting some level of gate-
keeping [34]. In addition, recruitment rates were higher in control than in intervention hospi-
tals. These factors may have resulted in unmeasured baseline differences between the study
groups, which may also explain the fact that mortality rates were higher in the intervention
than in the control arm. A systematic review of recruitment issues in palliative care
Table 4. ACP process and its evaluation by patients.
ACP process outcome Patients in intervention group (n = 442)
Patients who had ACP conversations; n (%) 396 (90)
Number of conversations per patient; mean (range) 1.3 (1–3)
Length of conversations in minutes; mean (SD, range) 93 (43; 4–303)
One or more relatives attended ACP conversation; n (%)
First conversation (n = 394) 262 (67)
Second conversation (n = 116) 95 (82)
Third conversation (n = 2) 2 (100)
Questions about the ACP process (n = 303)�
Evaluation of number of conversations; n (%)
Too few 30 (10)
Just right 265 (89)
Too many 3 (1)
Timing of ACP conversations; n (%)
Too early 48 (16)
Just right 228 (76)
Too late 25 (8)
ACP conversations considered to be helpful; n (%)
Not at all 18 (6)
A little 82 (27)
Quite a bit 119 (39)
Very much 84 (28)
ACP conversations considered distressing; n (%)
Not at all 171 (56)
A little 86 (28)
Quite a bit 32 (11)
Very much 14 (5)
�Questions about the ACP process were included in follow-up questionnaires 1 and 2. If a participant answered the
questions in both questionnaires, only the answers to follow-up questionnaire 2 were included.
ACP, advance care planning.
https://doi.org/10.1371/journal.pmed.1003422.t004
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randomised controlled trials identified a number of barriers to recruitment that also appeared
to be issues in this trial [34]. These include patients not being interested in the intervention,
the burden of illness, and gatekeeping by healthcare professionals. We also know from the gen-
eral literature that healthcare professionals struggle to introduce ACP and discuss end-of-life
care issues. Further research is required to explore the complexity of recruitment in palliative
care trials [35].
Second, information materials for the control groups also referred in some detail to the
intervention. Although we support this from an ethical viewpoint, the information may have
alerted patients in the control group to engage in decision-making processes and so may have
reduced the contrast between the groups. Third, analyses were carried out on survivors only,
whereas survivor average causal effect modelling or partly conditional inference could be a
more sophisticated approach to address truncation by death [36,37]. However, in our data no
significant differences were found in the proportion of patients who died between the inter-
vention and control arm, and these proportions were small, especially at follow-up assessment
1. Fourth, the number of ACP conversations was limited to an average of 1.3 per patient. This
may have affected the impact of the ACP programme. Finally, attrition of patients, although
expected in this population, was rather high. Despite these limitations, the trial provides rigor-
ous evidence of the effect of an internationally recognised programme. The results suggest
both the challenges of timely discussion of preferences—and aligning the care of patients with
advanced cancer accordingly—and the relevance of conducting randomised evaluation of
interventions such as ACP programmes.
Several studies outside Europe have reported positive effects of comparable ACP programmes
on various outcomes. For instance, the RC programme was found to increase satisfaction with
care among older hospitalised patients in Australia [18]. RC facilitation improved the ACP
knowledge and decreased the willingness to undergo life-sustaining treatments of ambulatory
geriatric patients in the US [38]. However, in a recent study into the effects of facilitated ACP
among frail older people in a Dutch population, no effects on quality of life were found [39].
The lack of comprehensive evidence of a positive impact of the complex ACP intervention
evaluated in this study may be explained by (1) 1 or more of the characteristics of the interven-
tion, (2) choice and timing of outcome measures, or (3) patients’ preferences regarding ACP
and ADs.
The first explanation relates to potential inadequacies of the intervention. We could not
ensure that ACP documents were routinely completed, included in the medical notes, and
acted upon by physicians. Also, the intervention was delivered in a research context, which
required standardisation. As a result, the programme was not integrated with routine services,
nor adapted to local circumstances and needs, which may have reduced its effect. For future
research we would recommend exploring all options for broader involvement at the institu-
tional level. Further, although patients were offered 2 conversations, the number of ACP con-
versations was limited to an average of 1.3 per patient. This may have affected the impact of
the ACP programme.
The second potential explanation is that the choice and timing of outcome measurements
may have been suboptimal. Our primary outcome measure was quality of life, operationalised
by the EORTC emotional functioning items, at 11–12 weeks of follow-up. In 2017, a large
international Delphi panel agreed that quality of life is not the most appropriate outcome of
ACP [6]. Goal-concordant care might have been a better primary outcome, but is very difficult
to measure because a validated measure to assess goal-concordant care is lacking [40]. Other
studies have discussed the complexity of determining the right outcome measure of ACP stud-
ies as well [16,39,41]. Effects of ACP could also predominantly occur in the relational domain:
patients and relatives may indeed have been supported to discuss and exchange views about
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values, goals, and preferences, but this outcome was not explicitly assessed in our trial. The
qualitative data as collected in the ACTION trial may shed some light on these potential effects.
Although we checked medical files up until death for some patients, the timing of our outcome
measurement may have been suboptimal: effects may occur at a later stage for at least some
patients, at a time when their situation deteriorates and actual decisions have to be made.
The third potential explanation is that patients may prefer not to fully engage in ACP or
make ADs. At the start of the study, the concept of ACP was almost unknown in Denmark
[42], Italy, and Slovenia, and ADs had no legal status in Italy [17,43]. The lower recruitment
rate in the intervention arm suggests that engaging in ACP in a study context was not attrac-
tive for all patients, the majority of whom received anti-cancer treatment. This is supported by
16% of participants reporting the ACP conversations to be distressing. Further, patients may
feel reluctant to document specific preferences as these preferences may change [44], or
patients may not consider documentation meaningful, either because they find it hard to
envisage the future or because they trust their family or physician to decide what is best.
We conclude that in our large trial in European patients with advanced cancer, we did not
find effects of the ACTION RC ACP intervention on quality of life, coping, patient satisfaction,
or shared decision-making. Potential explanations relate to characteristics of the intervention,
patients’ preferences regarding ACP, and the choice of outcome measures. The increase in use
of specialist palliative care and of inclusion of ADs in hospital files among patients who
received the intervention is meaningful and requires further study. Our findings suggest that
additional approaches to support patient-centred end-of-life care and to improve quality of life
in this population are needed.
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